Dupont Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Dupont Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,567	Closed	-$652K	–	1776
2022 Q3	$652K	Buy	+9,567	New	+$528K	0.04%	544
2020 Q4	–	Sell	-5,255	Closed	-$290K	–	1450
2020 Q3	$290K	Sell	5,255 -1,107	-17%	-$70.4K	0.01%	989
2020 Q2	$402K	Buy	+6,362	New	+$436K	0.01%	865
2020 Q1	–	Sell	-7,770	Closed	-$618K	–	1408
2019 Q4	$618K	Hold	7,770	–	–	0.01%	739
2019 Q3	$377K	Sell	7,770 -833	-10%	-$43.4K	0.01%	897
2019 Q2	$453K	Hold	8,603	–	–	0.01%	832
2019 Q1	$455K	Hold	8,603	–	–	0.01%	790
2018 Q4	$353K	Buy	8,603 +998	+13%	+$37.4K	0.01%	850
2018 Q3	$289K	Hold	7,605	–	–	0.01%	830
2018 Q2	$344K	Sell	7,605 -9,843	-56%	-$448K	0.01%	795
2018 Q1	$843K	Sell	17,448 -683	-4%	-$38.1K	0.02%	559
2017 Q4	$713K	Buy	+18,131	New	+$677K	0.02%	582

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Dupont Capital Management's GBT Position: Q4 2022 in Review

Dupont Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 9,567 shares — an estimated $652K sold.

Dupont Capital Management first reported a position in GBT in Q4 2017 and held it in 12 quarters. The position peaked at $843K in Q1 2018. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Dupont Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Dupont Capital Management sold 9,567 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $652K.
Dupont Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
Dupont Capital Management's Global Blood Therapeutics, Inc. position peaked at $843K in Q1 2018.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.